Determinants of improvement in epicardial flow and myocardial perfusion for ST elevation myocardial infarction; insights from TIMI 14 and InTIME-II.
暂无分享,去创建一个
E. Antman | K. Anderson | E. Braunwald | F. Van de Werf | S. Murphy | J. D. de Lemos | C. Gibson | C. McCabe | H. Cooper | R. Giugliano | P. Coussement | J. Scherer | C. Mccabe
[1] InTIME-II Investigators,et al. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. , 2000, European heart journal.
[2] E. Antman,et al. Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II. , 2000, The American journal of cardiology.
[3] E. Antman,et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. , 2000, European heart journal.
[4] E. Antman,et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Thrombolysis in Myocardial Infarction (TIMI) 14 investigators. , 2000, The American journal of cardiology.
[5] E. Antman,et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. , 2000, Circulation.
[6] D. Freimark,et al. The significance of persistent ST elevation versus early resolution of ST segment elevation after primary PTCA. , 1999, Journal of the American College of Cardiology.
[7] E. Antman,et al. Determinants of coronary blood flow after thrombolytic administration. TIMI Study Group. Thrombolysis in Myocardial Infarction. , 1999, Journal of the American College of Cardiology.
[8] E. Antman,et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.
[9] G. Schulz,et al. Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. , 1999, Journal of the American College of Cardiology.
[10] U. Deligonul,et al. The clinical implications of no reflow demonstrated with intravenous perfluorocarbon containing microbubbles following restoration of Thrombolysis In Myocardial Infarction (TIMI) 3 flow in patients with acute myocardial infarction. , 1998, The American journal of cardiology.
[11] T. Sakuma,et al. Prediction of short- and intermediate-term prognoses of patients with acute myocardial infarction using myocardial contrast echocardiography one day after recanalization. , 1998, Journal of the American College of Cardiology.
[12] H. Suryapranata,et al. Influence of treatment delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with primary angioplasty. , 1998, Journal of the American College of Cardiology.
[13] J. Rawles,et al. Quantification of the benefit of earlier thrombolytic therapy: five-year results of the Grampian Region Early Anistreplase Trial (GREAT). , 1997, Journal of the American College of Cardiology.
[14] E. Braunwald,et al. TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.
[15] K Wegscheider,et al. Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. , 1995, Journal of the American College of Cardiology.
[16] K. Wegscheider,et al. Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction. , 1994, Journal of the American College of Cardiology.
[17] C. Fry,et al. Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.
[18] Fibrinolytic Therapy Trialists' Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994, The Lancet.
[19] Johan Herlitz,et al. Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .
[20] Gusto Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.
[21] A. Kitabatake,et al. Lack of Myocardial Perfusion Immediately After Successful Thrombolysis: A Predictor of Poor Recovery of Left Ventricular Function in Anterior Myocardial Infarction , 1992, Circulation.
[22] S. Holmberg. Thrombolysis in acute myocardial infarction. , 1992, British journal of hospital medicine.
[23] Dwight E. Peake,et al. Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .
[24] R Roberts,et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.
[25] Harold T. Dodge,et al. Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .